PA
ARHS icon

PharVision Advisers’s Arhaus ARHS Stock Holding History

PharVision Advisers’s Portfolio ARHS Stock Details ARHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,178
Closed -$69K – 68
2026
Q1 		$69K Sell
10,178
-9,181
-47% -$83.4K 0.7% 75
2025
Q4 		$217K Sell
19,359
-11,200
-37% -$116K 0.11% 494
2025
Q3 		$325K Buy
+30,559
New +$322K 0.18% 183

Other funds holding ARHS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

PharVision Advisers's ARHS Position: Q2 2026 in Review

PharVision Advisers sold out of Arhaus (ARHS) in Q2 2026, closing a stake of 10,178 shares — an estimated $69K sold.

PharVision Advisers first reported a position in ARHS in Q3 2025 and held it in 3 quarters. The position peaked at $325K in Q3 2025. 165 funds tracked by Wall St. Rank hold ARHS as of Q2 2026.

  • PharVision Advisers reported no remaining Arhaus position as of Q2 2026 after selling out during the quarter.
  • PharVision Advisers sold 10,178 Arhaus shares in Q2 2026, an estimated $69K.
  • PharVision Advisers first reported a position in Arhaus in Q3 2025 and held it in 3 quarters.
  • PharVision Advisers's Arhaus position peaked at $325K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Arhaus as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.